BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30120556)

  • 1. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.
    Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J
    Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
    Lavolé A; Danel S; Baudrin L; Gounant V; Ruppert AM; Epaud C; Belmont L; Rosencher L; Cadranel J; Milleron B
    Bull Cancer; 2012 Apr; 99(4):E43-8. PubMed ID: 22450449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.
    Mense ES; Smit AAJ; Crul M; Franssen EJF
    J Clin Pharm Ther; 2019 Apr; 44(2):249-257. PubMed ID: 30578577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
    Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
    J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
    Dana R; Kachhwaha VS
    Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
    Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
    Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
    Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
    Aoyama T; Tsunoda T; Kato H; Hagino A; Furutani R; Ito K; Yoshioka H; Nakamura M; Hiraide M; Kawakami K; Kobayashi K; Suzuki K; Ichimura T; Yamaguchi K; Hama T
    J Chemother; 2020 May; 32(3):144-150. PubMed ID: 31960769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A short outpatient hydration schedule for cisplatin administration.
    Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
    Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
    Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
    J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
    Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
    J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
    Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
    Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
    Prasaja Y; Sutandyo N; Andrajati R
    Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
    Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.